Join
Live feed
·
PRReleasevia Quantisnow
Insmed Incorporated logo

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

ByQuantisnow·Wall Street's wire, on your screen.
INSM· Insmed Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INSM (Insmed Incorporated) and more on Quantisnow.